Product Description
GeoVax obtained rights from the U.S. NIH to develop MVA as a vaccine for smallpox and Mpox (GEO-MVA), as well as also having rights from the NIH to use MVA as a vaccine vector. GeoVax also holds exclusive rights to use the City of Hope Medical Center's synthetic MVA (sMVA) platform for the manufacture and distribution of COVID-19 vaccines including GEO-CM04S1, our multi-antigenic COVID-19 vaccine currently in multiple Phase 2 studies. (Sourced from: https://www.geovax.com/technology/mva-technology-overview)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GeoVax
Company Location: SMYRNA GA 30080
Company CEO: David A. Dodd
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Monkeypox
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|